Royalty Pharma (RPRXN) Stock Price & Analysis
RPRXN Stock Chart & Stats
- Day’s Range
- MXN 1,213.52 - MXN 1,250.00
- 52-Week Range
- MXN 666.41 - MXN 1,250.00
- Previous Close
- MXN 1,213.52
- Volume
- 0
- Average Volume (3M)
- 137
- Market Cap
- MXN 722.26B
- Enterprise Value
- MXN 42.30B
- Total Cash (Recent Filing)
- MXN 836.99M
- Total Debt (Recent Filing)
- MXN 8.96B
- Price to Earnings (P/E)
- 27.5
- Beta
- 0.15
- Next Earnings
- Nov 04, 2026 (Est.)
- EPS Estimate
- 22.25
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 1.33%
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation
Royalty Pharma converts a high proportion of its earnings into cash, providing durable funding for debt service, shareholder returns, and new royalty acquisitions. Improving operating cash flow and 5.0x coverage of net income strengthen financial resilience across the next several quarters.
High-margin Royalty Model
The royalty model produces exceptionally high operating margins because Royalty Pharma generally avoids the direct development, manufacturing, and commercialization costs borne by product owners. Persistent margin strength supports attractive cash generation and reinvestment capacity.
Growing Recurring Portfolio Receipts
Higher guidance for recurring royalty receipts indicates continued underlying portfolio growth rather than reliance solely on occasional milestones. A larger recurring base can improve predictability, support capital deployment, and expand the cash resources available for future portfolio development.
Bears Say
Meaningful And Rising Leverage
The rising debt burden reduces financial flexibility if portfolio receipts weaken or acquisition opportunities require additional funding. Although profitability and cash generation provide support, maintaining debt service capacity will depend on continued royalty receipts and disciplined capital allocation.
Product Exclusivity And Policy Headwinds
These product-specific pressures can reduce royalty receipts from important portfolio assets over the coming periods. Their inclusion in guidance suggests that portfolio growth must offset known erosion from exclusivity loss, biosimilar competition, and possible pricing or reimbursement effects.
Development-stage Outcome Risk
Part of the portfolio’s future value depends on clinical assets that have not yet established commercial success. A disappointing pivotal outcome could reduce expected royalty economics and delay returns on invested capital, making development-stage expansion less predictable than receipts from approved medicines.
Royalty Pharma News
RPRXN FAQ
What was Royalty Pharma’s price range in the past 12 months?
What is Royalty Pharma’s market cap?
When is Royalty Pharma’s upcoming earnings report date?
How were Royalty Pharma’s earnings last quarter?
Is Royalty Pharma overvalued?
Does Royalty Pharma pay dividends?
What is Royalty Pharma’s EPS estimate?
How many shares outstanding does Royalty Pharma have?
What happened to Royalty Pharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Royalty Pharma?
What is the TipRanks Smart Score and how is it calculated?
Royalty Pharma Stock Smart Score
Company Description
Royalty Pharma
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Pablo Legorreta
- Employees
- 100
- Website
- www.royaltypharma.com
- Address
- 110 East 59th Street, New York, NY, 10022, US
Royalty Pharma (RPRXN) Earnings & Revenues
RPRXN Company Deck
RPRXN Earnings Call
Earnings Call SentimentPositive
The call emphasized multiple strong positives: double‑digit recurring cash flow growth, raised full‑year guidance, disciplined capital deployment (including a strategic cliramitug purchase), expanded development‑stage pipeline with high historical success rates, robust cash generation, and an investment‑grade credit upgrade. Lowlights were present but largely manageable: a material decline in milestone/contract receipts (one‑time prior period effect), specific product headwinds (Promacta, biosimilar Tysabri, IRA), dependence on future pivotal trial outcomes for some investments, modestly higher expected operating expense rates in H2, and geopolitical/regulatory uncertainty in China. Overall, the positives—strong growth, improved guidance, financial flexibility, and portfolio expansion—substantially outweigh the risks and near‑term headwinds.
View all MX:RPRXN earnings summariesRPRXN Net sales Breakdown
- 93.34% Income from financial royalty assets
- 6.62% Other royalty income
- 0.04% Revenue from intangible royalty assets
RPRXN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 2 | 5 |
| Technical Analysis | 3 | 2 | 5 |
| Moving Averages | 12 | 0 | 0 |
